Lumena Pharmaceuticals Secures $45M in Series B Financing

lumena_logoLumena Pharmaceuticals, a San Diego, CA-based biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, secured $45m in Series B financing.

The round was led by New Enterprise Associates (NEA) with participation from Adage Capital Management and RA Capital Management, which joined existing investors Pappas Ventures, RiverVest Venture Partners and Alta Partners. In conjunction with the funding, Ed Mathers, partner, NEA, will join Lumena’s board of directors in conjunction with the financing.

Led by Mike Grey, president and CEO, Founded in 2011 by Pappas Ventures, Lumena is developing:
– LUM001, its lead candidate, for the treatment of rare cholestatic liver disease in pediatric and adult patients, and
– LUM002 for the treatment of nonalcoholic steatohepatitis (NASH).

The company intends to use the funds to advance the clinical development of their products.

FinSMEs

11/03/2014

Related News
08/05/2013: Lumena Pharmaceuticals Secures $23M in Series A Financing

Join the discussion